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NCoR is a corepressor of several transcription factors, including the PPAR family of nuclear recep-
tors in fat and muscle. By specifically deleting NCoR in these tissues, Li et al. and Yamamoto et al.
now uncover an important role for NCoR in regulating lipid homeostasis through the coordinated
control of different nuclear receptors.Nuclear receptors are a family of tran-
scription factors that play a key role in
receiving signals and modulating re-
sponses that drive lipid and carbohydrate
metabolism (Rosen and Spiegelman,
2006). Nuclear receptors also control the
development of specific types of fat and
muscle cells, which are crucial for main-
taining metabolic balance (Spiegelman
and Heinrich, 2004). These diverse func-
tions of nuclear receptors are regulated
by the properties of the complexes they
form in response to ligand binding (Perissi
et al., 2010). When nuclear receptors are
not bound to ligand, they interact with
corepressor proteins that maintain them
in the inactive state. Upon ligand binding,
nuclear receptors dissociate from these
silencing factors and assemble with coac-
tivators, which then modulate histone
acetylation or chromatin remodeling.
Many nuclear receptors are regulated in
this fashion, but perhaps the best-studied
group is the PPAR family. These proteins
form complexes with coactivators, such
as CBP, PGC-1, and CRTC2, and with
the corepressors NCoR and SMRT
(Chen and Evans, 1995). Although the
coactivators have received great atten-
tion, it is not well understood how the
corepressors modulate energy metabo-
lism. In this issue of Cell, two studies
(Li et al., 2011; Yamamoto et al., 2011)
shed important light on the physiological
role of the corepressor NCoR, including
how it regulates the transcriptional activity
of PPARg and hownutritional statusmight
coordinate responses to caloric excess
by controlling its expression.
Constitutive deletion of NCoR is embry-
onically lethal in mice and causes defectsin multiple organs. Olefsky and coworkers
(Li et al., 2011) generate mice with the
NCoR gene specifically deleted in adi-
pose tissue. When fed normal chow,
these mice display few changes com-
pared to wild-type animals, but they gain
excessive weight when placed on a
high-fat diet. Interestingly, this adipose-
specific deletion of NCoR induces similar
phenotypes in the diet-induced obese
mice as those observed when PPARg
is activated by thiazolidinedione (TZD)
ligands, including improved insulin sensi-
tivity in fat, liver, and muscle and de-
creased hepatic steatosis (i.e., fatty liver).
The targeted deletion of NCoR also pro-
duces a gene expression profile similar
to that seen with TZDs. However, these
mutant mice did not undergo hemodilu-
tion (i.e., increased fluid in the plasma) or
cardiomegaly (i.e., an enlarged heart),
two well-established side effects of
TZDs. These results indicate that activa-
tion of PPARg specifically in adipose
tissue can account for the beneficial
insulin-sensitizing effects of TZDs, where-
as activation in other tissue, perhaps the
kidneys, is responsible for the cardiovas-
cular liabilities of TZDs (Guan et al., 2005).
In addition, these mutant mice show
dramatically reduced inflammation in fat.
They have fewer M1-polarized macro-
phages (i.e., a subtype of macrophages
that produces proinflammatory cyto-
kines), and they display an increased
proportion of M2-like macrophages
(i.e., a subtype of macrophages with
anti-inflammatory properties) (Lumeng
et al., 2007). Fat cells from the mutant
mice generate reduced macrophage
chemotaxis and are less responsive toCell 147, Nmacrophage-conditioned media when
compared to the fat cells from wild-type
animals. Together, these results indicate
that activation of PPARg represses both
the production of and response to inflam-
matory signals in fat cells of obese mice.
Deleting NCoR also provides new
insights into the mechanism of PPARg
regulation. Phosphorylation of PPARg by
CDK5 blocks the transcriptional activity
of PPARg. Inflammatory cytokines, such
as TNFa, can stimulate CDK5, whereas
thiazolidinedionesandother ligands inhibit
phosphorylation by the kinase (Choi et al.,
2010). In a seriesofbindingstudies, Li et al.
show that NCoR directly modulates the
phosphorylation state of PPARg. When
bound to the nuclear receptor, NCoR
recruits CDK5 into the complex, which
facilitates PPARg phosphorylation and
repression of its activity. Once NCoR is
dissociated due to ligand binding, PPARg
remains free from CDK5, unphosphory-
lated, and transcriptionally active.
In an independent study, Auwerx and
colleagues (Yamamoto et al., 2011)
examine the effects of deleting NCoR in
skeletal muscle. Although these mutant
mice display only modest changes in
glucose and lipid homeostasis while on
a high-fat diet, they exhibit a substantial
increase in oxidative metabolism, mito-
chondrial content, and muscle fiber size.
Compared to the wild-type animals, the
mutant mice also display an increase in
reprogramming to oxidative muscle and
better exercise capacity.
Though the effects of disrupting NCoR
in the adipose tissue can be attributed
largely to the full activation of PPARg,
the transcription factor partners of NCoRovember 11, 2011 ª2011 Elsevier Inc. 717
Figure 1. AHypothetical Model for the Coordinated Actions of NCoR
in Muscle and Fat
NCoR is a corepressor of nuclear receptors, including PPARg in adipocytes
and PPARd or estrogen-related receptor (ERR) in myocytes. When bound
to these transcription factors, NCoR maintains their activity in the basal
state. High-fat diet drives down NCoR expression in both tissues, allowing
coactivators to bind the nuclear receptors and initiate transcription. In
fat cells, this increases lipogenesis and adipogenesis; in muscle, it increases
fat oxidation and mitochondrial biogenesis (Li et al., 2011; Yamamoto
et al., 2011).in muscle are less certain.
Some analyses of transcrip-
tional complexes suggest
that PPARd and estrogen-
related receptor (ERR) are
likely to play important roles
in generating this phenotype.
It will be interesting to deter-
mine whether phosphoryla-
tion regulates these recep-
tors, as with PPARg.
Interestingly, Yamamoto
et al. also demonstrate that
NCoR itself is acutely regu-
lated by nutritional status.
Whereas insulin increases the
appearance of NCoR in the
nucleus, exposure of cells to
low glucose with high fatty
acids reduces levels of NCoR
messenger RNA and protein.
Likewise, extensive exercise
or a high-fat diet reduces
NCoR expression in fat and
possibly in muscle (although
protein levels are not exam-ined). Although it is currently unknown
how the NCoR gene is controlled, both in
terms of expression levels and protein
location, these data by Yamamoto and
colleagues suggest that downregulating
NCoR by excess fat can support lipid
oxidation in muscle via derepression of
mitochondrial biogenesis and activity.
Together, the studies by Li et al. and
Yamamoto et al. indicate that regulation
of NCoR levels by energy substrates
may coordinate metabolic adaptation to
either caloric excess or deficiency
(Figure 1). NCoR normally keeps the tran-
scriptional activity of its nuclear receptor
partners in a basal state. In the case of
PPARg in adipocytes, this involves
enhancing the binding of CDK5, which
ensures that the receptor is phosphory-
lated and inactive. Thus, NCoR ‘‘keeps
a lid’’ on lipogenesis and adipogenesis
via PPARg. In muscle, NCoR reduces
activity of PPARd and ERR, maintaining
mitochondrial activity at basal levels and
favoring glucose oxidation at the expense
of lipid oxidation. When a high-fat diet
introduces an excess of calories, it trig-
gers an adaptive downregulation of
NCoR in both muscle and adipose tissue,718 Cell 147, November 11, 2011 ª2011 Elseresulting in the increased activity of its
partner receptors. This boosts lipogen-
esis and adipogenesis to provide
a storage site for increased fat intake
(mimicked by treatment with TZDs), with
a coordinated increase in fat oxidation in
muscle to maintain energy balance. At
the same time, decreased expression of
NCoR in fat and possibly in muscle can
counteract the effects of obesity-induced
inflammation, perhaps as a homeostatic
mechanism to maintain inflammation in
a low-grade state and promote energy
balance within the adipocyte.
Several important questions remain
about the role of NCoR in metabolic
adaptation. For example,manyother tran-
scription factors partner with NCoR. How
are these factors influenced by the
decreased expression of the corepressor,
and how do these factors impact metabo-
lism, particularly in the liver, heart, and
brain? Then, what about NCoR’s first
cousinSMRT,which shares a similar over-
all structure with NCoR and can form a
complex with nuclear receptors? Several
reports indicate that steroid hormones,
cytokines, and other factors might regu-
late the expression or cellular localizationvier Inc.of NCoR (Perissi et al., 2010).
How might these contribute
to metabolic homeostasis
through NCoR regulation,
and what pathways are
involved? Finally, how can
NCoR’s regulation of PPARg
phosphorylation (andpossibly
other transcription factors)
help us develop new ligands
(Choi et al., 2011) to tweak
the properties of these multi-
protein complexes and drive
metabolism in a beneficial
direction without unwanted
side effects? No doubt
these and other questions
will spark renewed interest in
understanding the pleiotropic
actions of corepressors.REFERENCES
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